Heron Therapeutics | HRTX - Pre Tax Profit


Heron Therapeutics reported $-2.95M in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
ALKERMES USD 60.38M 40.36M Dec/2025
Alnylam Pharmaceuticals USD 221.65M 60.52M Mar/2026
Amarin USD -852K 7.26M Dec/2025
ANI Pharmaceuticals USD 49.52M 39M Sep/2025
Anika Therapeutics USD 764K 3M Dec/2025
Arrowhead Research USD 28.27M 7.85M Dec/2025
Eisai JPY 22B 7.47B Dec/2025
Esperion Therapeutics USD 63.67M 95M Dec/2025
GlaxoSmithKline GBP 2.14B 919M Mar/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Insmed USD -326.93M 41.77M Dec/2025
Ligand Pharmaceuticals USD 141.14M 102M Sep/2025
Merck USD 3.42B 3.32B Dec/2025
Nektar Therapeutics USD -34.7M 2.35M Dec/2025
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Omeros USD -65.12M 21.27M Jun/2024
Pacira USD 571K 8.95M Dec/2025
Regeneron Pharmaceuticals USD 1.04B 719.6M Dec/2025
Roche Holding CHF 4.79B 3.01B Jun/2025
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Surmodics USD -5.9M 1.61M Jun/2025
Ultragenyx Pharmaceutical USD -184M 56M Mar/2026
Veracyte USD 40.63M 21.74M Dec/2025
Vertex Pharmaceuticals USD 1.33B 32.2M Dec/2025